Publication at First Faculty of Medicine |
2014
Abstract
Belimumab is fully humanized recombinan IgG1 monoclonal antibody with ability to block soluble BLyS (soluble B lymphocyte stimulator) from binding on B lymphocytes. Belimumab is the first approved biological drug for treatment of systemic lupus erythematosus by FDA (U.
S. Food and Drug Administration) and EMA (European Medicines Agency).
Belimumab is approved for patients with SLE without renal or neurological manifestations. Belimumab was subject of clinical studies in different autoimmune disorders (Sjogren syndrome, ANCA associated vasculitis) and others.
This review was focused on belimumab - characteristic, indication, safety and resuls of selected clinical studies. The efficiency of belimumab was presented on case report.